Global Bronchodilators Market: Current Analysis and Forecast (2021-2027)

Global Bronchodilators market is expected to register a CAGR of around ~5% over the period of 2021-2027. Bronchodilators are drugs that open up (dilate) the breathing passages by relaxing the bronchial smooth muscle. They make breathing easier for people with asthma or other lung conditions. Thus, the increase in the number of patients with respiratory disorders, and the treatment of various diseases such as asthma, chronic obstructive pulmonary disease, and others. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Moreover, the development of advanced bronchodilators by major companies and the diagnostics industry owing to the presence of well-established market players and frequent product launches in the region. For instance, in July 2020, EVA Pharma launched 'Inhalex', the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half.

Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., SANOFI, Teva Pharmaceutical Industries Ltd., Vectura Group Plc are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst indication, asthma category is expected to witness the highest CAGR during the forecast period"

Based on indication, the market is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. Among these, asthma is expected to witness the highest CAGR during the forecast period owing to the rising prevalence of asthma worldwide. For instance, as per World Health Organization (WHO) data, asthma affected around 262 million people in 2019 and triggered 461,000 deaths worldwide. In addition, the increase in the prevalence of pulmonary disorders is increasing the growth of the bronchodilators market.

"Amongst the drug type, anticholinergics bronchodilators are expected to highest CAGR during the forecast period"

Based on drug type, the market is categorized into beta-adrenergic bronchodilators, anticholinergic bronchodilators, phosphodiesterase inhibitors, combination drugs, and others. Among these, the anticholinergic bronchodilators are expected to witness the highest CAGR during the forecast period as it is available in both long-acting and short-acting forms. Anticholinergics act by inhibiting the effect of acetylcholine on airways and nasal passages. It is widely used to treat chronic obstructive pulmonary disease. According to, institute for Health Metrics and Evaluation (IHME), Chronic respiratory diseases were responsible for 71.1 million YLLs and 32.4 million YLDs in 2019. Chronic obstructive pulmonary disease (COPD) and asthma were the two largest contributors to the global respiratory disease burden.

"North America to significant share during the forecast period"

North America accounted for a prominent share of the global bronchodilators market and is expected to grow at a significant growth rate during the forecast period owing to the quick adoption of bronchodilators technologies along with the high incidence of COPD and asthma cases. The United States Environmental Protection Agency and the National Health Interview Surveys (NHIS), in April 2021, estimated that almost 25.1 million people, comprising 5.1 million children, have asthma in the country. In addition, Major healthcare companies are investing heavily in their products due to rising social awareness among healthcare industry experts, medical professionals, and patients about the benefits that bronchodilators have to prompt the regulatory authorities to consider and authorize the bronchodilators.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global Bronchodilators market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.